Highbridge Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Highbridge Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-363	Closed	-$230K	–	1873
2015 Q2	$230K	Buy	363 +173	+91%	+$91.9K	﹤0.01%	1235
2015 Q1	$98K	Sell	190 -97	-34%	-$48.9K	﹤0.01%	1316
2014 Q4	$154K	Buy	+287	New	+$129K	﹤0.01%	1083
2014 Q3	–	Sell	-245	Closed	-$336K	–	1411
2014 Q2	$336K	Buy	+245	New	+$284K	﹤0.01%	838
2014 Q1	–	Sell	-186	Closed	-$186K	–	1283
2013 Q4	$186K	Buy	+186	New	+$192K	﹤0.01%	978

Other funds holding VIRX

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Highbridge Capital Management's VIRX Position: Q3 2015 in Review

Highbridge Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2015, closing a stake of 363 shares — an estimated $230K sold.

Highbridge Capital Management first reported a position in VIRX in Q4 2013 and held it in 5 quarters. The position peaked at $336K in Q2 2014. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2015.

Highbridge Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
Highbridge Capital Management sold 363 Viracta Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $230K.
Highbridge Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2013 and held it in 5 quarters.
Highbridge Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $336K in Q2 2014.
59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Highbridge Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.